Publicidad
Artículo original 01 de octubre de 2001

Papel de la ventriculografía isotópica en el seguimiento de pacientes oncológicos sometidos a tratamiento con antraciclinas

Referenciar Imprimir Descargar PDF

Referencias

  1. Ferriere M, Donadio D, Ramirez R. Cardiotoxicity of anthracyclines. Arch Mal Coeur Vaiss 1993;86:53-8.
  2. Nousiainen T, Vanninen E, Jantunene E, Remes J, Kuikka J, Hartikainen J. Anthracycline induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol 2001;21:123-8.
  3. Agarwala S, Kumar R, Bhatnagar V, Bjapai M, Gupta DK, Mitra DK. Hidh incidence of adriamycin cardiotoxicity in children ene at low cumulative doses: role of radionuclide cardiac angiography. J Pediatr Surg 2000;35:1786-9.
  4. Carlson RW. Reducing the cardiotoxicity of the antracyclines. Oncology 1992;6:95-100.
  5. Steinberg JS, Wasserman AG. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity. Clin Ther 1985;7:660-7.
  6. Yabuta M. Evaluation of cardiotoxicity by radionuclide angiocardiography in chemotherapy of gynecologic malignances. Nippon Gan Chiryo Gakkai Shi 1990;25:1146-56.
  7. Geidel S, Gran M, Gravinghoff L, Hausdorf G, Morf G, Bielack S et al. Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamicyn. Klin Padiatr 1991;203:257-61.
  8. Barendswaard EC, Prpic H, Van der Wall EE, Camps JA, Keizer HJ, Pauwels EK. Right ventricle wall motion abnormalities in patients treated with chemotherapy. Clin Nucl Med 1991;16:513-6.
  9. Sarubbi B, Orditura M, Ducceschi V, De Vita F, Santangelo L, Ciaramella F et al. Ventricular repolarization time indexes following anthracycline treatment. Heart Vessels 1997;12:262-6.
  10. Nakada S, Ogawa S, Hirayama T. Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography. Nippon Ika Daigaku Zasshi 1994;61:209-19.
  11. Valdes Olmos RA, ten Bokkel huinink WW, ten Hoeve RF, van Tinteren H, Bruning PF, van Vlies B et al. Assessment of anthracycline-related myocardial adrenergic derangement by 123I-metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31:26-31.
  12. Carrio I, Estorch M, Berna L, lopez-Pousa J, Tabernero J, Torres G. Indium-11-antimyosin and iodine-123-MIBG studies in early assessment of doxorrubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.
  13. Hatfield MK, Martoin WB, Ryan JW, Vokes EE, Vogelzang NJ. Cardiac gallium uptake in doxorrubicin-induced cardiotoxicity. Clin Nucl Med 1986;11:756-7.
  14. Casáns I, Lluch A, Jimeno J, Ciudad J, Losada A, García-Conde J et al. Ventriculografía isotópica en el seguimiento de la cardiotoxicidad inducida por 4-epi-adriamicina. Rev Esp Cardiol 1988;41:89-96.
  15. Jain KK, Casper ES, Geller NL ET AL. A prospective randomized comparison of epirrubicin and doxorrubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818-26.
  16. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and deleyed clinical cardiotoxicity of doxorrubicin. Cancer 1985;55:2761-5.
  17. Nousiainen T, Janutunen E, Vannien E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorrubicin treatment for non-Hodgkin's lymphoma. Eur J Haemaltol 1999;62:135-41.